Related Experiment Video

Updated: Oct 21, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.4K

Atorvastatin calcium tablets on inflammatory factors, hemorheology and renal function damage indexes in patients with

Ronghua Li1, Tianting Shi2, Enpeng Xing3

  • 1Ronghua Li Department of Nephrology, Binzhou People's Hospital, Shandong, 256600, China.

Pakistan Journal of Medical Sciences
|September 3, 2021
PubMed

Insights

Atorvastatin effectively improved kidney function and reduced inflammation in diabetic nephropathy (DN) patients. The study found significant improvements in hemorheology and inflammatory markers after three months of treatment.

Area of Science:

  • Nephrology
  • Cardiovascular Pharmacology
  • Metabolic Disorders

Background:

  • Diabetic nephropathy (DN) is a significant complication of diabetes, leading to progressive renal damage.
  • Inflammation and altered hemorheology are key contributors to DN progression.
  • Current treatments for DN have limitations in addressing these underlying pathological mechanisms.

Purpose of the Study:

  • To evaluate the therapeutic effects of atorvastatin on inflammatory factors, hemorheology, and renal function in patients with DN.
  • To compare the efficacy of atorvastatin combined with conventional treatment versus conventional treatment alone.

Main Methods:

  • A randomized controlled trial involving 106 DN patients over three months.
  • Patients received either conventional treatment or conventional treatment plus atorvastatin.
  • Key indicators assessed included hemorheology (whole blood viscosity, erythrocyte aggregation, fibrinogen), renal function markers (MIF, VCAM-1, SFRP5, mAIb/Cr), and inflammatory factors (CRP, IL-1, TNF-α).

Main Results:

  • Atorvastatin treatment led to significant reductions in whole blood viscosity, erythrocyte aggregation index, fibrinogen (FIB), macrophage migration inhibitory factor (MIF), vascular cell adhesion molecule (VCAM)-1, and albumin-to-creatinine ratio (mAIb/Cr).
  • Significant decreases in inflammatory markers, including C-reactive protein (CRP), interleukin-1 (IL-1), and tumor necrosis factor-α (TNF-α), were observed in the atorvastatin group.
  • Levels of Secreted frizzled-related protein-5 (SFRP5) significantly increased in the observation group compared to the control group.

Conclusions:

  • Atorvastatin demonstrates significant efficacy in alleviating renal function damage in DN patients.
  • The drug effectively reduces serum inflammatory factors and improves hemorheological parameters.
  • Atorvastatin holds considerable clinical value for the management of diabetic nephropathy.
Abstract

Keywords:
AtorvastatinDiabetic nephropathyHemorheologyRenal function damage

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.1K
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

718

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
971
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
70
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
927
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
173
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
92
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
581